NCT07553650

Brief Summary

The Stroke-CORE cohort aims to provide a comprehensive and up-to-date understanding of stroke care in Germany. To achieve this, patients are followed along the entire continuum of care-from initial management before hospital admission, through acute treatment, rehabilitation, and follow-up care, to the prevention of recurrent strokes. Strokes occurring in childhood are also included in this cohort study. In addition, the study seeks to establish effective structures for the early identification and inclusion of patients in clinical research (screening). In this context, structured screening processes are being implemented across all levels of care at participating sites within the Network University Medicine (NUM), a collaboration of German university hospitals. At the same time, the cohort serves as a platform within this network to systematically address open research questions in various areas of stroke care and to support the targeted planning and conduct of future clinical studies. The study includes patients with ischemic stroke (caused by a blocked blood vessel) or intracerebral hemorrhage (bleeding within the brain). Participation takes place in different thematic modules, each focusing on specific aspects of the disease course and its management. These modules address, among other topics, acute hospital treatment, measures to prevent recurrent strokes (secondary prevention), possible complications, pre-hospital care, rehabilitation, follow-up care, and long-term outcomes such as physical recovery, independence in daily life, and cognitive functions including memory and concentration. As part of the study, a range of data is collected. This includes sociodemographic information (such as age and living situation) as well as medical data, for example on prior conditions, diagnoses, treatments, and comorbidities. In addition, patients' health status is assessed at multiple time points in order to better understand the course of the disease. Depending on the level of participation, data collection may be complemented by the collection of biological samples, such as blood. These are obtained either during routine clinical procedures or through simple, minimally burdensome (non-invasive) methods. The study is structured into several levels that differ in the scope and depth of data collection. The basic level includes essential information, while higher levels involve more detailed assessments. In addition, some levels include the collection of biological samples, and there are optional supplementary modules in which patients may participate voluntarily. This tiered approach allows participation to be flexibly adapted to the individual situation while contributing to a nuanced and comprehensive understanding of stroke care.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12,750

participants targeted

Target at P75+ for all trials

Timeline
51mo left

Started May 2026

Longer than P75 for all trials

Geographic Reach
1 country

12 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 13, 2026

Completed
15 days until next milestone

First Posted

Study publicly available on registry

April 28, 2026

Completed
3 days until next milestone

Study Start

First participant enrolled

May 1, 2026

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2030

Last Updated

April 28, 2026

Status Verified

April 1, 2026

Enrollment Period

4.2 years

First QC Date

April 13, 2026

Last Update Submit

April 23, 2026

Conditions

Keywords

Strokeischemic strokeIntracerebral HemorrhagePaediatric StrokeCerebrovascular DisordersBrain DiseasesVascular DiseasesCardiovascular DiseasesBrain InfarctionEmbolic StrokeThrombotic StrokeAcute

Outcome Measures

Primary Outcomes (1)

  • adaptive research platform addressing various and for the 3 groups different research questions

    Outcomes include disease severity, standard of care, complications, recurrent ischaemic or haemorrhagic stroke, burden and impact of disease and treatment on quality of life, functional outcome and survival at different time points. Since SN Stroke is an adaptive research platform addressing various research questions, additional outcomes and different determinants influencing these outcomes may be added in each module.

    Depending on the group, outcome measures will be collected through study completion, primarily at baseline, follow-up at 3 and/or 6 months, and annually, with an average follow-up period expected to be 1 year.

Study Arms (3)

Ischemic Stroke

This module aims to collect comprehensive, longitudinal data on patients with acute IS to characterise clinical and imaging-derived predictors of outcome. The module is embedded within the broader cohort framework (Level 1) and focuses specifically on causes of IS, treatment during the acute phase, as well as complications, and secondary prevention. Data collection and follow up measures is aligned with the routine collection of quality-assurance data from the German Stroke Registers Study Group ('Arbeitsgemeinschaft Deutschsprachiger Schlaganfall Register' \[ADSR\], https://www.schlaganfallregister.org) and the ICHOM Standard Set for Stroke (https://www.ichom.org/patient-centered-outcome-measure/stroke/).

Intracerebral Hemorrhage

This module aims to collect data on adult patients presenting with spontaneous intracerebral haemorrhage (ICH). Participants will be characterised regarding demographics, clinical factors, treatment, and imaging features, including haematoma size, location, expansion dynamics, and the presence of spot sign. The study will aim to identify baseline clinical and imaging predictors of in-hospital and 3-month mortality and functional independence, to explore subgroups with distinct prognostic trajectories, and to investigate associations between clinical presentation, imaging parameters, and post-stroke complications. These analyses will inform risk stratification, guide neuroprotective and acute management strategies, and support the development of tailored interventional approaches in ICH.

Paediatric Stroke

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Stroke patients with criteria defined in each individual Module (IS, ICH, peadiatric stroke) who are admitted to one of the participating university hospitals in Germany within 24 hours of symptom onset. General inclusion and exclusion criteria: * Fulfilment of all inclusion and no exclusion criteria for at least one Module * Signed IC from patients capable of giving consent and understanding all content of the IC or IC of an appropriate patient representative, if patients are unable to provide consent themselves.

You may qualify if:

  • Diagnosis of AIS or ICH; the AIS diagnosis may be diagnosed clinically or radiologically (i.e., focal neurological impairment of sudden onset, lasting more than 24 hours and of presumed vascular origin, or with proof of cerebral ischaemia corresponding to the clinical symptoms in neuroimaging); for ICH diagnosis requires clinical symptoms and radiological diagnosis of ICH
  • Hospital admission \<24h after symptom onset
  • Age 18+ years for the basic Modules AIS and ICH; age \<18 years for the basic Module paediatric stroke patients
  • Informed consent: Signed IC from patients capable of giving consent and understanding all content of the IC or IC of an appropriate patient representative or deferred consent, if patients are unable to consent themselves

You may not qualify if:

  • In-hospital stroke
  • TIA
  • SAH
  • Stroke as a complication of a medical procedure
  • Enrolment in a randomised placebo-controlled interventional trial
  • Already enrolled in the SN STROKE base cohort

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (12)

Universitätsklinikum Hamburg-Eppendorf (UKE)

Hamburg, Free and Hanseatic City of Hamburg, 20246, Germany

Location

Charité University, Berlin, Germany

Berlin, State of Berlin, 10117, Germany

Location

Universität Bielefeld, Universitätsklinikum OWL, Evangelisches Klinikum Bethel gGmbH,

Bielefeld, 33617, Germany

Location

Universitätsklinikum Carl Gustav Carus Dresden

Dresden, 01307, Germany

Location

Universitätsklinikum Erlangen

Erlangen, 91054, Germany

Location

Universitätsklinikum Essen

Essen, 45147, Germany

Location

Universitätsklinikum Heidelberg

Heidelberg, 69120, Germany

Location

Universitätsklinikum Leipzig

Leipzig, 04103, Germany

Location

Universitätsklinikum Schleswig-Holstein (UKSH), Campus Lübeck

Lübeck, 23538, Germany

Location

Ludwig Maximilians Universität Klinikum

München, 81377, Germany

Location

Universitätsklinikum Tübingen

Tübingen, 72076, Germany

Location

Universitätsklinikum Würzburg

Würzburg, 97080, Germany

Location

Related Publications (45)

  • NCT04965038. Early reperfusion therapy with intravenous alteplase for recovery of VISION in acute central retinal artery occlusion (REVISION). clinicaltrials.gov/study/NCT04965038

    BACKGROUND
  • NCT04371055. Intensive rhythm monitoring to decrease ischemic stroke and systemic embolism - the Find-AF 2 study (Find-AF2). clinicaltrials.gov/study/NCT04371055

    BACKGROUND
  • NCT04159324. StroCare - optimised cross-sectoral, coordinated treatment of stroke patients with patient-orientated outcome measurement (StroCare). clinicaltrials.gov/study/NCT04159324

    BACKGROUND
  • NCT03930121. Transcranial direct current stimulation to enhance training effectiveness in chronic post-stroke aphasia. clinicaltrials.gov/study/NCT03930121

    BACKGROUND
  • NAKO. (2025). Level 3 Projekte - NAKO Gesundheitsstudie. Retrieved 19.01.2026 from https://nako.de/forschung/forschungsprojekte/level-3-projekte/

    BACKGROUND
  • Wachter R, Weber-Kruger M, Hamann GF, Kermer P, Liman J, Mende M, Seegers J, Wasser K, Groschel S, Uphaus T, Poppert H, Kohrmann M, Zabel M, Laufs U, Heuschmann PU, Conen D, Groschel K; Find-AFRANDOMISED Investigators and Coordinators. Long-Term Follow-up of Enhanced Holter-Electrocardiography Monitoring in Acute Ischemic Stroke. J Stroke. 2022 Jan;24(1):98-107. doi: 10.5853/jos.2021.01207. Epub 2021 Dec 17.

    PMID: 34911255BACKGROUND
  • Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, Avezum A, Diaz R, Hohnloser SH, Lewis BS, Shestakovska O, Wang J, Connolly SJ. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J. 2015 Feb 1;36(5):281-7a. doi: 10.1093/eurheartj/ehu307. Epub 2014 Sep 3.

    PMID: 25187524BACKGROUND
  • Turc G, Hadziahmetovic M, Walter S, Churilov L, Larsen K, Grotta JC, Yamal JM, Bowry R, Katsanos AH, Zhao H, Donnan G, Davis SM, Hussain MS, Uchino K, Helwig SA, Johns H, Weber JE, Nolte CH, Kunz A, Steiner T, Sacco S, Ebinger M, Tsivgoulis G, Fassbender K, Audebert HJ. Comparison of Mobile Stroke Unit With Usual Care for Acute Ischemic Stroke Management: A Systematic Review and Meta-analysis. JAMA Neurol. 2022 Mar 1;79(3):281-290. doi: 10.1001/jamaneurol.2021.5321.

    PMID: 35129584BACKGROUND
  • Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, Cheripelli B, Cho TH, Fazekas F, Fiehler J, Ford I, Galinovic I, Gellissen S, Golsari A, Gregori J, Gunther M, Guibernau J, Hausler KG, Hennerici M, Kemmling A, Marstrand J, Modrau B, Neeb L, Perez de la Ossa N, Puig J, Ringleb P, Roy P, Scheel E, Schonewille W, Serena J, Sunaert S, Villringer K, Wouters A, Thijs V, Ebinger M, Endres M, Fiebach JB, Lemmens R, Muir KW, Nighoghossian N, Pedraza S, Gerloff C; WAKE-UP Investigators. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. N Engl J Med. 2018 Aug 16;379(7):611-622. doi: 10.1056/NEJMoa1804355. Epub 2018 May 16.

    PMID: 29766770BACKGROUND
  • Thomalla G, Boutitie F, Ma H, Koga M, Ringleb P, Schwamm LH, Wu O, Bendszus M, Bladin CF, Campbell BCV, Cheng B, Churilov L, Ebinger M, Endres M, Fiebach JB, Fukuda-Doi M, Inoue M, Kleinig TJ, Latour LL, Lemmens R, Levi CR, Leys D, Miwa K, Molina CA, Muir KW, Nighoghossian N, Parsons MW, Pedraza S, Schellinger PD, Schwab S, Simonsen CZ, Song SS, Thijs V, Toni D, Hsu CY, Wahlgren N, Yamamoto H, Yassi N, Yoshimura S, Warach S, Hacke W, Toyoda K, Donnan GA, Davis SM, Gerloff C; Evaluation of unknown Onset Stroke thrombolysis trials (EOS) investigators. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data. Lancet. 2020 Nov 14;396(10262):1574-1584. doi: 10.1016/S0140-6736(20)32163-2. Epub 2020 Nov 8.

    PMID: 33176180BACKGROUND
  • Stockert A, Wawrzyniak M, Klingbeil J, Wrede K, Kummerer D, Hartwigsen G, Kaller CP, Weiller C, Saur D. Dynamics of language reorganization after left temporo-parietal and frontal stroke. Brain. 2020 Mar 1;143(3):844-861. doi: 10.1093/brain/awaa023.

    PMID: 32068789BACKGROUND
  • Stahl B, Millrose S, Denzler P, Lucchese G, Jacobi F, Floel A. Intensive Social Interaction for Treatment of Poststroke Depression in Subacute Aphasia: The CONNECT Trial. Stroke. 2022 Dec;53(12):3530-3537. doi: 10.1161/STROKEAHA.122.039995. Epub 2022 Sep 20.

    PMID: 36124755BACKGROUND
  • Schwarzbach CJ, Eichner FA, Rucker V, Hofmann AL, Keller M, Audebert HJ, von Bandemer S, Engelter ST, Geis D, Groschel K, Haeusler KG, Hamann GF, Meisel A, Sander D, Schutzmeier M, Veltkamp R, Heuschmann PU, Grau AJ; SANO study group. The structured ambulatory post-stroke care program for outpatient aftercare in patients with ischaemic stroke in Germany (SANO): an open-label, cluster-randomised controlled trial. Lancet Neurol. 2023 Sep;22(9):787-799. doi: 10.1016/S1474-4422(23)00216-8. Epub 2023 Jul 14. Erratum In: Lancet Neurol. 2023 Nov;22(11):e12. doi: 10.1016/S1474-4422(23)00382-4.

    PMID: 37459876BACKGROUND
  • Salinas J, Sprinkhuizen SM, Ackerson T, Bernhardt J, Davie C, George MG, Gething S, Kelly AG, Lindsay P, Liu L, Martins SC, Morgan L, Norrving B, Ribbers GM, Silver FL, Smith EE, Williams LS, Schwamm LH. An International Standard Set of Patient-Centered Outcome Measures After Stroke. Stroke. 2016 Jan;47(1):180-6. doi: 10.1161/STROKEAHA.115.010898. Epub 2015 Nov 24.

    PMID: 26604251BACKGROUND
  • Nolte CH, von Rennenberg R, Litmeier S, Leistner DM, Szabo K, Baumann S, Mengel A, Michalski D, Siepmann T, Blankenberg S, Petzold GC, Dichgans M, Katus H, Pieske B, Regitz-Zagrosek V, Braemswig TB, Rangus I, Pepic A, Vettorazzi E, Zeiher AM, Scheitz JF, Wegscheider K, Landmesser U, Endres M. Type 1 Myocardial Infarction in Patients With Acute Ischemic Stroke. JAMA Neurol. 2024 Jul 1;81(7):703-711. doi: 10.1001/jamaneurol.2024.1552.

    PMID: 38829625BACKGROUND
  • Montellano FA, Rucker V, Ungethum K, Penalba A, Hotter B, Giralt M, Wiedmann S, Mackenrodt D, Morbach C, Frantz S, Stork S, Whiteley WN, Kleinschnitz C, Meisel A, Montaner J, Haeusler KG, Heuschmann PU. Biomarkers to improve functional outcome prediction after ischemic stroke: Results from the SICFAIL, STRAWINSKI, and PREDICT studies. Eur Stroke J. 2024 Dec;9(4):968-980. doi: 10.1177/23969873241250272. Epub 2024 May 6.

    PMID: 38711254BACKGROUND
  • Mishra A, Malik R, Hachiya T, Jurgenson T, Namba S, Posner DC, Kamanu FK, Koido M, Le Grand Q, Shi M, He Y, Georgakis MK, Caro I, Krebs K, Liaw YC, Vaura FC, Lin K, Winsvold BS, Srinivasasainagendra V, Parodi L, Bae HJ, Chauhan G, Chong MR, Tomppo L, Akinyemi R, Roshchupkin GV, Habib N, Jee YH, Thomassen JQ, Abedi V, Carcel-Marquez J, Nygaard M, Leonard HL, Yang C, Yonova-Doing E, Knol MJ, Lewis AJ, Judy RL, Ago T, Amouyel P, Armstrong ND, Bakker MK, Bartz TM, Bennett DA, Bis JC, Bordes C, Borte S, Cain A, Ridker PM, Cho K, Chen Z, Cruchaga C, Cole JW, de Jager PL, de Cid R, Endres M, Ferreira LE, Geerlings MI, Gasca NC, Gudnason V, Hata J, He J, Heath AK, Ho YL, Havulinna AS, Hopewell JC, Hyacinth HI, Inouye M, Jacob MA, Jeon CE, Jern C, Kamouchi M, Keene KL, Kitazono T, Kittner SJ, Konuma T, Kumar A, Lacaze P, Launer LJ, Lee KJ, Lepik K, Li J, Li L, Manichaikul A, Markus HS, Marston NA, Meitinger T, Mitchell BD, Montellano FA, Morisaki T, Mosley TH, Nalls MA, Nordestgaard BG, O'Donnell MJ, Okada Y, Onland-Moret NC, Ovbiagele B, Peters A, Psaty BM, Rich SS, Rosand J, Sabatine MS, Sacco RL, Saleheen D, Sandset EC, Salomaa V, Sargurupremraj M, Sasaki M, Satizabal CL, Schmidt CO, Shimizu A, Smith NL, Sloane KL, Sutoh Y, Sun YV, Tanno K, Tiedt S, Tatlisumak T, Torres-Aguila NP, Tiwari HK, Tregouet DA, Trompet S, Tuladhar AM, Tybjaerg-Hansen A, van Vugt M, Vibo R, Verma SS, Wiggins KL, Wennberg P, Woo D, Wilson PWF, Xu H, Yang Q, Yoon K; COMPASS Consortium; INVENT Consortium; Dutch Parelsnoer Initiative (PSI) Cerebrovascular Disease Study Group; Estonian Biobank; PRECISE4Q Consortium; FinnGen Consortium; NINDS Stroke Genetics Network (SiGN); MEGASTROKE Consortium; SIREN Consortium; China Kadoorie Biobank Collaborative Group; VA Million Veteran Program; International Stroke Genetics Consortium (ISGC); Biobank Japan; CHARGE Consortium; GIGASTROKE Consortium; Millwood IY, Gieger C, Ninomiya T, Grabe HJ, Jukema JW, Rissanen IL, Strbian D, Kim YJ, Chen PH, Mayerhofer E, Howson JMM, Irvin MR, Adams H, Wassertheil-Smoller S, Christensen K, Ikram MA, Rundek T, Worrall BB, Lathrop GM, Riaz M, Simonsick EM, Korv J, Franca PHC, Zand R, Prasad K, Frikke-Schmidt R, de Leeuw FE, Liman T, Haeusler KG, Ruigrok YM, Heuschmann PU, Longstreth WT, Jung KJ, Bastarache L, Pare G, Damrauer SM, Chasman DI, Rotter JI, Anderson CD, Zwart JA, Niiranen TJ, Fornage M, Liaw YP, Seshadri S, Fernandez-Cadenas I, Walters RG, Ruff CT, Owolabi MO, Huffman JE, Milani L, Kamatani Y, Dichgans M, Debette S. Stroke genetics informs drug discovery and risk prediction across ancestries. Nature. 2022 Nov;611(7934):115-123. doi: 10.1038/s41586-022-05165-3. Epub 2022 Sep 30.

    PMID: 36180795BACKGROUND
  • Masouris I, Kellert L, Pradhan C, Wischmann J, Schniepp R, Muller R, Fuhry L, Hamann GF, Pfefferkorn T, Remi JM, Schoberl F. Telemedical stroke care significantly improves patient outcome in rural areas: Long-term analysis of the German NEVAS network. Int J Stroke. 2024 Jun;19(5):577-586. doi: 10.1177/17474930241234259. Epub 2024 Feb 28.

    PMID: 38346936BACKGROUND
  • Luengo-Fernandez R, Violato M, Candio P, Leal J. Economic burden of stroke across Europe: A population-based cost analysis. Eur Stroke J. 2020 Mar;5(1):17-25. doi: 10.1177/2396987319883160. Epub 2019 Oct 29.

    PMID: 32232166BACKGROUND
  • Kopczak A, Schindler A, Sepp D, Bayer-Karpinska A, Malik R, Koch ML, Zeller J, Strecker C, Janowitz D, Wollenweber FA, Hempel JM, Boeckh-Behrens T, Cyran CC, Helck A, Harloff A, Ziemann U, Poli S, Poppert H, Saam T, Dichgans M. Complicated Carotid Artery Plaques and Risk of Recurrent Ischemic Stroke or TIA. J Am Coll Cardiol. 2022 Jun 7;79(22):2189-2199. doi: 10.1016/j.jacc.2022.03.376. Epub 2022 May 3.

    PMID: 35523659BACKGROUND
  • Jensen M, Suling A, Metzner A, Schnabel RB, Borof K, Goette A, Haeusler KG, Zapf A, Wegscheider K, Fabritz L, Diener HC, Thomalla G, Kirchhof P. Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial. Lancet Neurol. 2023 Jan;22(1):45-54. doi: 10.1016/S1474-4422(22)00436-7.

    PMID: 36517170BACKGROUND
  • Hotter B, Ulm L, Hoffmann S, Katan M, Montaner J, Bustamante A, Meisel A. Selection bias in clinical stroke trials depending on ability to consent. BMC Neurol. 2017 Dec 4;17(1):206. doi: 10.1186/s12883-017-0989-9.

    PMID: 29202730BACKGROUND
  • Hensel L, Lange F, Tscherpel C, Viswanathan S, Freytag J, Volz LJ, Eickhoff SB, Fink GR, Grefkes C. Recovered grasping performance after stroke depends on interhemispheric frontoparietal connectivity. Brain. 2023 Mar 1;146(3):1006-1020. doi: 10.1093/brain/awac157.

    PMID: 35485480BACKGROUND
  • Haeusler KG, Kirchhof P, Kunze C, Tutuncu S, Fiessler C, Malsch C, Olma MC, Jawad-Ul-Qamar M, Kramer M, Wachter R, Michalski D, Kraft A, Rizos T, Groschel K, Thomalla G, Nabavi DG, Rother J, Laufs U, Veltkamp R, Heuschmann PU, Endres M; MonDAFIS Investigators. Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study. Lancet Neurol. 2021 Jun;20(6):426-436. doi: 10.1016/S1474-4422(21)00067-3.

    PMID: 34022169BACKGROUND
  • Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, Davalos A, Majoie CB, van der Lugt A, de Miquel MA, Donnan GA, Roos YB, Bonafe A, Jahan R, Diener HC, van den Berg LA, Levy EI, Berkhemer OA, Pereira VM, Rempel J, Millan M, Davis SM, Roy D, Thornton J, Roman LS, Ribo M, Beumer D, Stouch B, Brown S, Campbell BC, van Oostenbrugge RJ, Saver JL, Hill MD, Jovin TG; HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016 Apr 23;387(10029):1723-31. doi: 10.1016/S0140-6736(16)00163-X. Epub 2016 Feb 18.

    PMID: 26898852BACKGROUND
  • Gladstone DJ, Wachter R, Schmalstieg-Bahr K, Quinn FR, Hummers E, Ivers N, Marsden T, Thornton A, Djuric A, Suerbaum J, von Grunhagen D, McIntyre WF, Benz AP, Wong JA, Merali F, Henein S, Nichol C, Connolly SJ, Healey JS; SCREEN-AF Investigators and Coordinators. Screening for Atrial Fibrillation in the Older Population: A Randomized Clinical Trial. JAMA Cardiol. 2021 May 1;6(5):558-567. doi: 10.1001/jamacardio.2021.0038.

    PMID: 33625468BACKGROUND
  • Geisler T, Keller T, Martus P, Poli K, Serna-Higuita LM, Schreieck J, Gawaz M, Tunnerhoff J, Bombach P, Nagele T, Klose U, Aidery P, Groga-Bada P, Kraft A, Hoffmann F, Hobohm C, Naupold K, Niehaus L, Wolf M, Bazner H, Liman J, Wachter R, Kimmig H, Jung W, Huber R, Feurer R, Lindner A, Althaus K, Bode FJ, Petzold GC, Nguyen TN, Mac Grory B, Schrag M, Purrucker JC, Zuern CS, Ziemann U, Poli S; ATTICUS Investigators. Apixaban versus Aspirin for Embolic Stroke of Undetermined Source. NEJM Evid. 2024 Jan;3(1):EVIDoa2300235. doi: 10.1056/EVIDoa2300235. Epub 2023 Dec 22.

    PMID: 38320511BACKGROUND
  • Geisler F, Kunz A, Winter B, Rozanski M, Waldschmidt C, Weber JE, Wendt M, Zieschang K, Ebinger M, Audebert HJ; Stroke Emergency Mobile (STEMO) Consortium. Telemedicine in Prehospital Acute Stroke Care. J Am Heart Assoc. 2019 Mar 19;8(6):e011729. doi: 10.1161/JAHA.118.011729.

    PMID: 30879372BACKGROUND
  • GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021 Oct;20(10):795-820. doi: 10.1016/S1474-4422(21)00252-0. Epub 2021 Sep 3.

    PMID: 34487721BACKGROUND
  • Frank B, Lembeck T, Toppe N, Brune B, Bozkurt B, Deuschl C, Nogueira RG, Dudda M, Risse J, Kill C, Forsting M, Kleinschnitz C, Kohrmann M. FAST-ED scale smartphone app-based prediction of large vessel occlusion in suspected stroke by emergency medical service. Ther Adv Neurol Disord. 2021 Nov 14;14:17562864211054962. doi: 10.1177/17562864211054962. eCollection 2021.

    PMID: 34804205BACKGROUND
  • Ferriero DM, Fullerton HJ, Bernard TJ, Billinghurst L, Daniels SR, DeBaun MR, deVeber G, Ichord RN, Jordan LC, Massicotte P, Meldau J, Roach ES, Smith ER; American Heart Association Stroke Council and Council on Cardiovascular and Stroke Nursing. Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke. 2019 Mar;50(3):e51-e96. doi: 10.1161/STR.0000000000000183.

    PMID: 30686119BACKGROUND
  • Feigin VL, Brainin M, Norrving B, Martins S, Sacco RL, Hacke W, Fisher M, Pandian J, Lindsay P. World Stroke Organization (WSO): Global Stroke Fact Sheet 2022. Int J Stroke. 2022 Jan;17(1):18-29. doi: 10.1177/17474930211065917. Erratum In: Int J Stroke. 2022 Apr;17(4):478. doi: 10.1177/17474930221080343.

    PMID: 34986727BACKGROUND
  • Eyding J, Bartig D, Weber R, Katsanos AH, Weimar C, Hacke W, Krogias C. Inpatient TIA and stroke care in adult patients in Germany - retrospective analysis of nationwide administrative data sets of 2011 to 2017. Neurol Res Pract. 2019 Dec 1;1:39. doi: 10.1186/s42466-019-0044-y. eCollection 2019.

    PMID: 33324904BACKGROUND
  • Endres M, Moro MA, Nolte CH, Dames C, Buckwalter MS, Meisel A. Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke. Circ Res. 2022 Apr 15;130(8):1167-1186. doi: 10.1161/CIRCRESAHA.121.319994. Epub 2022 Apr 14.

    PMID: 35420915BACKGROUND
  • Ebinger M, Siegerink B, Kunz A, Wendt M, Weber JE, Schwabauer E, Geisler F, Freitag E, Lange J, Behrens J, Erdur H, Ganeshan R, Liman T, Scheitz JF, Schlemm L, Harmel P, Zieschang K, Lorenz-Meyer I, Napierkowski I, Waldschmidt C, Nolte CH, Grittner U, Wiener E, Bohner G, Nabavi DG, Schmehl I, Ekkernkamp A, Jungehulsing GJ, Mackert BM, Hartmann A, Rohmann JL, Endres M, Audebert HJ; Berlin_PRehospital Or Usual Delivery in stroke care (B_PROUD) study group. Association Between Dispatch of Mobile Stroke Units and Functional Outcomes Among Patients With Acute Ischemic Stroke in Berlin. JAMA. 2021 Feb 2;325(5):454-466. doi: 10.1001/jama.2020.26345.

    PMID: 33528537BACKGROUND
  • Dunbar M, Kirton A. Perinatal stroke: mechanisms, management, and outcomes of early cerebrovascular brain injury. Lancet Child Adolesc Health. 2018 Sep;2(9):666-676. doi: 10.1016/S2352-4642(18)30173-1. Epub 2018 Jul 27.

    PMID: 30119760BACKGROUND
  • Diener HC, Sacco RL, Easton JD, Granger CB, Bar M, Bernstein RA, Brainin M, Brueckmann M, Cronin L, Donnan G, Gdovinova Z, Grauer C, Kleine E, Kleinig TJ, Lyrer P, Martins S, Meyerhoff J, Milling T, Pfeilschifter W, Poli S, Reif M, Rose DZ, Sanak D, Schabitz WR. Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups. Stroke. 2020 Jun;51(6):1758-1765. doi: 10.1161/STROKEAHA.119.028643. Epub 2020 May 14.

    PMID: 32404035BACKGROUND
  • Chamorro A, Lo EH, Renu A, van Leyen K, Lyden PD. The future of neuroprotection in stroke. J Neurol Neurosurg Psychiatry. 2021 Feb;92(2):129-135. doi: 10.1136/jnnp-2020-324283. Epub 2020 Nov 4.

    PMID: 33148815BACKGROUND
  • Busch MA, Kuhnert R. 12-Month prevalence of stroke or chronic consequences of stroke in Germany. J Health Monit. 2017 Mar 15;2(1):64-69. doi: 10.17886/RKI-GBE-2017-019. eCollection 2017 Mar.

    PMID: 37151304BACKGROUND
  • Breitenstein C, Grewe T, Floel A, Ziegler W, Springer L, Martus P, Huber W, Willmes K, Ringelstein EB, Haeusler KG, Abel S, Glindemann R, Domahs F, Regenbrecht F, Schlenck KJ, Thomas M, Obrig H, de Langen E, Rocker R, Wigbers F, Ruhmkorf C, Hempen I, List J, Baumgaertner A; FCET2EC study group. Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting. Lancet. 2017 Apr 15;389(10078):1528-1538. doi: 10.1016/S0140-6736(17)30067-3. Epub 2017 Mar 1.

    PMID: 28256356BACKGROUND
  • Bloos F, Bogatsch H, Netea MG, Giamarellos-Bourboulis EJ, Bauer M; SepNet Critical Care Trials Group. Effects of delayed consent on patient characteristics in adult patients with sepsis. Intensive Care Med. 2025 Jan;51(1):179-181. doi: 10.1007/s00134-024-07718-8. Epub 2024 Dec 12. No abstract available.

    PMID: 39665860BACKGROUND
  • Bosel J, Niesen WD, Salih F, Morris NA, Ragland JT, Gough B, Schneider H, Neumann JO, Hwang DY, Kantamneni P, James ML, Freeman WD, Rajajee V, Rao CV, Nair D, Benner L, Meis J, Klose C, Kieser M, Suarez JI, Schonenberger S, Seder DB; SETPOINT2 and the IGNITE Study Groups. Effect of Early vs Standard Approach to Tracheostomy on Functional Outcome at 6 Months Among Patients With Severe Stroke Receiving Mechanical Ventilation: The SETPOINT2 Randomized Clinical Trial. JAMA. 2022 May 17;327(19):1899-1909. doi: 10.1001/jama.2022.4798.

    PMID: 35506515BACKGROUND
  • Bendszus M, Fiehler J, Subtil F, Bonekamp S, Aamodt AH, Fuentes B, Gizewski ER, Hill MD, Krajina A, Pierot L, Simonsen CZ, Zelenak K, Blauenfeldt RA, Cheng B, Denis A, Deutschmann H, Dorn F, Flottmann F, Gellissen S, Gerber JC, Goyal M, Haring J, Herweh C, Hopf-Jensen S, Hua VT, Jensen M, Kastrup A, Keil CF, Klepanec A, Kurca E, Mikkelsen R, Mohlenbruch M, Muller-Hulsbeck S, Munnich N, Pagano P, Papanagiotou P, Petzold GC, Pham M, Puetz V, Raupach J, Reimann G, Ringleb PA, Schell M, Schlemm E, Schonenberger S, Tennoe B, Ulfert C, Valis K, Vitkova E, Vollherbst DF, Wick W, Thomalla G; TENSION Investigators. Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trial. Lancet. 2023 Nov 11;402(10414):1753-1763. doi: 10.1016/S0140-6736(23)02032-9. Epub 2023 Oct 11.

    PMID: 37837989BACKGROUND
  • Appel KS, Lee CH, Nunes de Miranda SM, Maier D, Reese JP, Anton G, Bahmer T, Ballhausen S, Balzuweit B, Bellinghausen C, Blumentritt A, Brechtel M, Chaplinskaya-Sobol I, Erber J, Fiedler K, Geisler R, Heyder R, Illig T, Kohls M, Kollek J, Krist L, Lorbeer R, Miljukov O, Mitrov L, Nurnberger C, Pape C, Pley C, Schafer C, Schaller J, Schattschneider M, Scherer M, Schulze N, Stahl D, Stubbe HC, Tamminga T, Tebbe JJ, Vehreschild MJGT, Wiedmann S, Vehreschild JJ. A precise performance-based reimbursement model for the multi-centre NAPKON cohorts - development and evaluation. Sci Rep. 2024 Jun 13;14(1):13607. doi: 10.1038/s41598-024-63945-5.

    PMID: 38871878BACKGROUND
  • Ahmadi M, Laumeier I, Ihl T, Steinicke M, Ferse C, Endres M, Grau A, Hastrup S, Poppert H, Palm F, Schoene M, Seifert CL, Kandil FI, Weber JE, von Weitzel-Mudersbach P, Wimmer MLJ, Algra A, Amarenco P, Greving JP, Busse O, Kohler F, Marx P, Audebert HJ. A support programme for secondary prevention in patients with transient ischaemic attack and minor stroke (INSPiRE-TMS): an open-label, randomised controlled trial. Lancet Neurol. 2020 Jan;19(1):49-60. doi: 10.1016/S1474-4422(19)30369-2. Epub 2019 Nov 7.

    PMID: 31708447BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

EDTA blood, PAX gene blood, residual tissue (e.g. thrombi)

MeSH Terms

Conditions

Cerebral HemorrhageStrokeIschemic StrokeCerebrovascular DisordersBrain DiseasesVascular DiseasesCardiovascular DiseasesBrain InfarctionEmbolic StrokeThrombotic Stroke

Condition Hierarchy (Ancestors)

Intracranial HemorrhagesCentral Nervous System DiseasesNervous System DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsBrain IschemiaInfarctionIschemiaNecrosis

Study Officials

  • Karen Gertz, Full professor, MD

    Charite University, Berlin, Germany

    PRINCIPAL INVESTIGATOR
  • Goetz Thomalla, Full professor, MD

    Universtätsklinikum Hamburg Eppendorf, Germany

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Johanna-Luise Kanwisch

CONTACT

Claudia Kunze

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
90 Days
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior Physician/ Head of Research Group

Study Record Dates

First Submitted

April 13, 2026

First Posted

April 28, 2026

Study Start

May 1, 2026

Primary Completion (Estimated)

June 30, 2030

Study Completion (Estimated)

June 30, 2030

Last Updated

April 28, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share

All collected IPD-including medical, biosamples, and imaging data as well as their analysis results-will be shared under strict governance. Secondary use is managed through defined Dynamic Use \& Access (DUA) procedures, aligned with the NUM Publication Policy and Terms of Use, ensuring recognition of contributing sites and researchers while maintaining high data protection standards. Applications must be submitted via a central application platform offering all required information and application documents. The DUA procedure includes: * Application submission * Formal review * Technical, scientific, and methodological evaluation * Decision by the relevant UA Committees * Data provision via a data transfer office following approval of the application. Data and biosamples are only released following rigorous review, ensuring compliance with ethical, legal, and data protection requirements. Use is limited to the analyses specified in the application.

Time Frame
At the earliest, following the first interim analysis, which is currently scheduled for mid-2027. Subject to future funding opportunities, the study itself and data sharing is planned to be conducted over the long term.
Access Criteria
Data, imaging data and biosamples of stroke patients may be requested by any natural or legal person. A request must be submitted in accordance with the procedures described above, must be scientifically justified, and must fit within the framework established by this protocol and, more importantly, the scope of the ICF signed by the patients in the study. Before data and biosamples of accepted applications are transferred, the applicant or someone from the application team must provide a positive vote or a waiver from the Ethics Committee responsible for the applicant.

Locations